# F.D.A. Rejects Closely Watched Lung Cancer Drug From China

Source: [NYT > Health](https://www.nytimes.com/2026/11/15/business/fda-lung-cancer-drug-china.html) · 2026-11-15 · Medicine
Page: https://themorning.science/story/f-d-a-rejects-closely-watched-lung-cancer-drug-from-china-b2fa6b946713c464
Kind: policy · Impact: medium

## In brief

- The U.S. Food and Drug Administration (FDA) has rejected ivonescimab, a lung cancer drug from China.
- The New York Times describes the drug as a closely watched symbol of China's rise in drug development.

## Why it matters

The decision affects whether this Chinese-developed lung cancer treatment can be marketed in the United States, and it bears on how regulators assess drugs developed largely outside the US.

## Timeline

- 2026-11-15: FDA rejects ivonescimab, reported by The New York Times

## Coverage

- [F.D.A. Rejects Closely Watched Lung Cancer Drug From China](https://www.nytimes.com/2026/11/15/business/fda-lung-cancer-drug-china.html) — NYT > Health, 2026-11-15

Tags: lung cancer, fda, drug approval, china, ivonescimab

---

Brief generated by AI (claude-haiku-5-5) from the reporting listed under Coverage. Headlines belong to their publishers. The Morning Science – https://themorning.science
